ClinicalTrials.gov
public full text
Public Domain
ARQ761 + PARP Inhibitor in Refractory Solid Tumors
Open Label, dose escalation in a 3+3 study design to establish the RP2D of the combination of ARQ761 and a PARP inhibitor, Olaparib
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors#1009079
- Study of DM5167 in Patients With Advanced Solid Tumors#1093553
- Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107 / Jutta Schmitz, Anna L. Bartkowiak, Nora Kolks, Patrick Petzsch, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert#1215051
- Advanced Refractory Solid Tumors With TP53 Mutations Register Study#1370335
- Olaparib for PAH: a Pilot Study#846331
Record · ID 1244530
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive